Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly and Company Aktie: Der Abwärtsdrift hält an

Der Pharmakonzern Eli Lilly and verzeichnete im vierten Quartal 2024 einen bemerkenswerten Umsatzanstieg von 45 Prozent auf 13,5 Milliarden US-Dollar.…

Eli Lilly: BofA says buy the dip after shares slide on Q4 miss By Investing.com

Eli Lilly: BofA says buy the dip after shares slide on Q4 miss…

Jim Cramer says he supports healthcare stocks for their long-term value

CNBCs Jim Cramer stresses the importance of investing for the long term, highlighting healthcare stocks Eli Lilly, Merck and Regeneron.…

US stocks end mixed in choppy session as inflation data eyed

STORY: U.S. stocks ended mixed on Tuesday as investors gauged the latest inflation data and braced for quarterly earnings reports…

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care…

Stocks making the biggest moves midday: Eli Lilly, Applied Digital, Boeing and more

These are the stocks posting the largest moves in midday trading.…

Eli Lilly, Robinhood Lead Market Cap Stock Movers on Tuesday By Investing.com

Eli Lilly, Robinhood Lead Market Cap Stock Movers on Tuesday…

Eli Lilly shares tumble after cutting its sales outlook. What it means for investors

Shares plunged 7% after management said demand for its popular GLP-1 drugs did not meet expectations.…

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet…

Hims & Hers stock up as Eli Lilly GLP-1 sales miss (LLY:NYSE)

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss drugmaker Hims…

Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow

Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.…

Eli Lilly shares drop following lower-than-expected preliminary Q4 revenue By Investing.com

Eli Lilly shares drop following lower-than-expected preliminary Q4 revenue…

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes…

Pharmakonzern Lilly erlöst 2024 weniger als gedacht

INDIANAPOLIS (dpa-AFX) - Der US-Pharmahersteller Lilly ist 2024 trotz eines Spurts vor Jahresende nicht so…

Lilly forecasts weak sales of weight-loss drug in fourth quarter

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in…

Eli Lilly issues 2025 revenue forecast ahead of market estimates By Investing.com

Eli Lilly issues 2025 revenue forecast ahead of market estimates…

Eli Lilly lowers FY revenue forecast as weight loss drug sales fall short

Shares in Eli Lilly and Co (NYSE:LLY) fell 7.3% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew…

Eli Lilly stumbles as weight-loss drug sales less than expected

Shares in Eli Lilly and Co fell 6.4% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly…

Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.

A $5,000 investment can go a long way, especially if youre loading up on fairly cheap stocks that may possess…

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate…

Lilly asks US government to pause drug price negotiation program, Bloomberg News reports

Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its…

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion…

Here are Mondays biggest analyst calls: Nvidia, Tesla, Meta, Alphabet, Netflix, Eli Lilly, 3M and more

Here are Mondays biggest calls on Wall Street.…

Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 bln

Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.…

Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 billion By Reuters

Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 billion…

Key deals this week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and more

…

Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade

…

Eli Lilly: Still Much Room To Ride The Weight-Loss Wave

…

Andreessen Horowitz, Eli Lilly to launch $500 million venture fund

The fund, Biotech Ecosystem Venture Fund, aims to invest in potentially relevant treatment platforms and "cutting-edge" technology companies.…

Cancer Immunotherapy Global Market Overview 2023-2030, Competitive Analysis of Amgen, AstraZeneca,Bayer, BMS, Eli Lilly, F. Hoffmann-La Roche, GSK, Immunocore, J&J, Merck, Novartis, Pfizer

The global cancer immunotherapy market is primarily driven by the rising prevalence of cancer worldwide, leading to a growing demand…

David Rubenstein Remembers Jimmy Carter

Carlyle Group co-founder and co-chairman and host of "Peer-to-Peer Conversations" David Rubenstein talks about the rising popularity of weight loss…

Eli Lilly’s Zepbound obesity drug covered by Medicare for sleep apnea

Eli Lilly and Co (NYSE:LLY)’s blockbuster obesity drug, Zepbound, can now be covered by Medicare plans for obstructive sleep apnea.…

LLY Falls Around 14% in 3 Months: How to Play the Stock

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth…

Medicare can now cover Eli Lillys Zepbound for sleep apnea, Health Department agency says

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many…

Eli Lillys lead in the obesity race has grown. Its recent stock performance says otherwise

Eli Lilly has been one of the worst-performing Club stocks over the past six months.…

Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Where to invest $1,000…

This Promising New Alzheimers Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world,…

Viele Aktien im Gesundheitswesen sind am Boden! Daraus resultieren einmalige Chancen

Ein Großteil des Gesundheitssektors steckt in Schwierigkeiten, von der Pharmaindustrie bis zu Krankenhäusern. Donald Trumps Wahlsieg löste im vergangenen November…

Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential

…

Prediction: These 3 Healthcare Stocks Will Soar in 2025

No one knows for sure what the new year will hold for the market. However, some stocks chances for success…

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.…

Lilly asks to join lawsuit over compounded versions of its weight-loss drugs

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug…

5 Large Drug Stocks to Keep An Eye On in the New Year

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY),…

Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to…

Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders

If youre looking for top stocks, theres no need to reinvent the wheel. The Securities and Exchange Commission makes it…

dpa-AFX ProFeed